Pulmonary arterial hypertension in systemic sclerosis
- PMID: 33548377
- DOI: 10.1016/j.lpm.2021.104062
Pulmonary arterial hypertension in systemic sclerosis
Abstract
Pulmonary arterial hypertension (PAH) is a frequent and severe complication of systemic sclerosis (SSc) due to combined vasculopathy and fibrogenesis. Early diagnosis and treatment are highly challenging in SSc-PAH and require referral to an expert PAH centre. Diagnostic algorithms evolved in the last decade. Novel therapeutic options notably targeting pulmonary vascular remodeling are needed.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis.Rheumatology (Oxford). 2020 Jul 1;59(7):1581-1586. doi: 10.1093/rheumatology/kez473. Rheumatology (Oxford). 2020. PMID: 31637433 Free PMC article.
-
Pulmonary Arterial Hypertension in Connective Tissue Diseases Beyond Systemic Sclerosis.Heart Fail Clin. 2023 Jan;19(1):45-54. doi: 10.1016/j.hfc.2022.08.016. Heart Fail Clin. 2023. PMID: 36435572 Review.
-
Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.Clin Exp Rheumatol. 2024 Aug;42(8):1590-1597. doi: 10.55563/clinexprheumatol/gzo4r2. Epub 2024 Mar 15. Clin Exp Rheumatol. 2024. PMID: 38489342
-
Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).Semin Arthritis Rheum. 2024 Dec;69:152554. doi: 10.1016/j.semarthrit.2024.152554. Epub 2024 Sep 13. Semin Arthritis Rheum. 2024. PMID: 39298973
-
Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.Medicina (Kaunas). 2024 Dec 27;61(1):19. doi: 10.3390/medicina61010019. Medicina (Kaunas). 2024. PMID: 39859001 Free PMC article. Review.
Cited by
-
Lung regeneration: diverse cell types and the therapeutic potential.MedComm (2020). 2024 Feb 23;5(2):e494. doi: 10.1002/mco2.494. eCollection 2024 Feb. MedComm (2020). 2024. PMID: 38405059 Free PMC article. Review.
-
Analysis of clinical features and risk factors of pulmonary hypertension associated with interstitial lung disease.Biomed Rep. 2025 Feb 4;22(4):58. doi: 10.3892/br.2025.1936. eCollection 2025 Apr. Biomed Rep. 2025. PMID: 39991007 Free PMC article.
-
Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis.Pharmaceuticals (Basel). 2025 Feb 14;18(2):259. doi: 10.3390/ph18020259. Pharmaceuticals (Basel). 2025. PMID: 40006072 Free PMC article.
-
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.Eur Respir Rev. 2024 Jun 12;33(172):240015. doi: 10.1183/16000617.0015-2024. Print 2024 Apr. Eur Respir Rev. 2024. PMID: 39009409 Free PMC article. Review.
-
Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.Clin Cosmet Investig Dermatol. 2023 May 25;16:1351-1361. doi: 10.2147/CCID.S409490. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37255624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical